Rein Therapeutics, Inc.

RNTX Nasdaq SEC CIK 1420565
Follow Rein Therapeutics Weekly email: filings, results

Financials

Reported figures only · latest: Q3 2026 USD · US GAAP
Revenue, last quarter $0
Net income −$5.5M +0.8% vs same quarter last year
EPS, diluted −$0.06 +71.4% vs same quarter last year
Operating cash flow −$7.3M −104.9% vs same quarter last year
Revenue by quarter
$0
$0
$0
$0
$0
$0
$0
$0
Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 Q3 26

Source: SEC XBRL filings · latest filing

The long view

Fiscal years as reported · SEC XBRL filings, US GAAP
Revenue and net income12 fiscal years
  • Revenue
  • Net income
−$80M−$60M−$40M−$20M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearRevenueNet income
FY25$0−$49.9M
FY24$0−$62.9M
FY23$0−$15.7M
FY22$0−$27.3M
FY21$0−$26.2M
FY20$0−$27.3M
FY19$0−$29.4M
FY18$0−$31.5M
FY17$0−$22.6M
FY16$0−$18.1M
FY15$0−$12.9M
FY14--
Free cash flowOperating cash flow minus capital expenditure
−$40M−$30M−$20M−$10M$0FY15FY17FY19FY21FY23FY25
Show the numbers
YearFree cash flow
FY25-
FY24-
FY23-
FY22-
FY21−$23.9M
FY20−$20.5M
FY19−$26.6M
FY18−$32.3M
FY17−$20.7M
FY16-
FY15−$11.8M
FY14-